---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pathophysiology"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pathophysiology. Topics: Activating GNAQ and GNA11 mutations; GNA11 and GNAQ Q209 mutations in primary tumors and metastases; Mutually exclusive G-protein pathway mutations: GNAQ, GNA11, CYSLTR2, and PLCB4; CYSLTR2 mutation as a uveal melanoma oncogene; 10 further topics. 14 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/pathophysiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Activating GNAQ and GNA11 mutations

> “Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.”
> “Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11.”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

<a id="topic-2.2.1.4-2"></a>

### GNA11 and GNAQ Q209 mutations in primary tumors and metastases

> “The frequency of mutations in GNA11 at the codon encoding Q209 increased progressively from blue nevi (6.5%) to primary uveal melanomas (31.9%) to uveal melanoma metastases (56.5%), a pattern inverse to the distribution of Q209 mutations in GNAQ, which are most common in blue nevi (54.7%) and least common in uveal melanoma metastases (21.7%) (P<0.001)”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

> “In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients.”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

<a id="topic-2.2.1.4-3"></a>

### Mutually exclusive G-protein pathway mutations: GNAQ, GNA11, CYSLTR2, and PLCB4

> “We found mutually exclusive somatic mutations in the G-protein pathway-associated GNAQ and/or GNA11 (92.5%), CYSLTR2 (4%), and PLCB4 (2.5%) genes”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.4-4"></a>

### CYSLTR2 mutation as a uveal melanoma oncogene

> “We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.”
> “The Leu129Gln CysLT2R mutant protein constitutively activates endogenous Gαq and is unresponsive to stimulation by leukotriene.”

Source: [Moore et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5032652/)

<a id="topic-2.2.1.4-5"></a>

### PLCB4 mutation as the downstream effector of Gαq signaling

> “PLCB4 p.D630Y mutations are mutually exclusive with mutations in GNA11 and GNAQ, consistent with PLCB4 being the canonical downstream target of the former gene products.”

Source: [Johansson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4826231/)

<a id="topic-2.2.1.4-6"></a>

### Protein kinase C and MAPK pathway activation downstream of GNAQ and GNA11

> “We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation.”
> “In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation, MAPK activation can be attributed to activated PKC.”

Source: [Chen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524511/)

<a id="topic-2.2.1.4-7"></a>

### Second driver event: BAP1, SF3B1, or EIF1AX

> “After the GNAQ/GNA11 mutation, a second driver event is necessary for malignant transformation. The premalignant cells either present loss of function BAP1 or mutations in SF3B1 or EIF1AX. This second hit also occurs in a mutually exclusive fashion.”

Source: [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/)

<a id="topic-2.2.1.4-8"></a>

### BAP1 inactivation in metastasizing tumors and chromosome 3 loss

> “Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors”
> “One copy of chromosome 3 was missing in all 17 BAP1-mutant class 2 tumors for which cytogenetic data were available, consistent with chromosome 3 loss uncovering recessive BAP1 mutations”

Source: [Harbour et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3087380/)

<a id="topic-2.2.1.4-9"></a>

### Four molecular subsets defined by chromosome 3 status, TCGA

> “Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM.”
> “EIF1AX and SF3B1 mutations in 27 of the 80 UM (34%) were nearly mutually exclusive”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.4-10"></a>

### Prognostic associations of BAP1, SF3B1, EIF1AX, MBD4, and PRAME

> “Biallelic BAP1 inactivation is associated with high risk of metastasis.”
> “Change-of-function SF3B1 mutations are associated with late metastasis.”
> “Mutations in EIF1AX are associated with a better prognosis.”
> “Mutations in MBD4 lead to a hypermutator phenotype, which has been correlated with improved response to immune checkpoint inhibitor (ICI) therapy.”
> “Expression of PRAME (preferentially expressed antigen of melanoma) is associated with a higher risk of metastases.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-11"></a>

### Low tumor mutational burden and absence of BRAF, NRAS, KIT, and NF1 mutations

> “In WES data for matched tumor-blood pairs, the median somatic mutation density of 1.1 per Mb was markedly lower than in CM”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

> “Uveal melanomas are molecularly distinct from cutaneous melanomas and lack mutations in BRAF, NRAS, KIT, and NF1.”

Source: [Moore et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5032652/)

<a id="topic-2.2.1.4-12"></a>

### Immunosuppressive tumor microenvironment

> “The UM microenvironment is characterised by high levels of tumour-promoting M2 macrophages, few active cytotoxic T cells and low programmed death-ligand 1 (PD-L1) expression.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-13"></a>

### Hematogenous spread and liver tropism

> “Because the uveal tract is a vascular structure without lymphatic channels, tumor spread occurs principally by local extension and by dissemination through the bloodstream.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “UM is characterised by early seeding and years of dormancy of micrometastases; the liver constitutes a specific niche, as numerous molecules like chemokine ligand 12 and chemokine receptor 4 (CXCL12/CXCR4) are involved in UM liver homing.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.4-14"></a>

### MET expression in primary tumors and liver metastases

> “Thirty-nine of 40 (98%) primary tumors and nine of 10 (90%) metastatic liver lesions expressed c-MET (H-score range 0-300).”
> “c-MET expression was significantly higher in metastatic compared with primary tumors (median H-score 190 vs. 30, P=0.022).”

Source: [Gardner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25211165/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
